Alan Biloski

About Alan Biloski

Dr. Biloski has led the seed round financings of a number of life science start-up companies in a diverse array of fields ranging from big data/AI to biotech and pharmaceutical services. As the lead pharma and biotech partner at Brock Capital, Dr. Biloski works with the independent fiduciary and family office groups to focus Brock Capital’s Opportunity Fund on the evaluation of direct investments in promising new companies. TRANSACTION HISTORY Eyetech (private placement)$ 109 MM Serono /$100 MM Regeneron Stock $ 100 MM Immunex – Sale of AHP-owned stock $2,783 MM Serono – Primary/Secondary stock offer $3,661 MM Pfizer / Warner Lambert $116,300 MM Medimmune / US BioScience $ 526 MM Roche / Genentech $ 4,800 MM Advanced Medicine (now Theravance ) Pvt Placement $ 160 MM Alkermes / Advanced Inhalation Research $ 110 MM Dow / Mycogen (Squeeze out 32%)$ 382 MM Dow Corning Chapter 11 Reorganization $1,500 MM Meridian Diagnostics / Gull Labs $ 18 MM Boston Scientific / Mintec $ 72 MM Aetna / US Healthcare $8,800 MM BASF Knoll / Hokuriku Seiyaku $ 339 MM CVC & JH Whitney / Medicon ND SmithKlineBeecham / PDS ND Pfizer / SmithKlineBeecham Animal Health $1,450 MM Bayer / SB Sterling Winthrop North America $2,930 MM SmithKlineBeecham / Sterling Winthrop OTC MM Hafslund Nycomed / Sterling Winthrop Rx $ 450 MM Thomas H. Lee / Thermoscan ND Rubbermaid / Carex ND SmithKlineBeecham / DPS sub of United Health $2,300 MM Burroughs Wellcome / Kodak SWIC ND Smiths Industries / Intertech $ 110 MM Baxter (Defense) Fujisawa/Lyphomed $1,100 MM Gambro/Hospal $ 400 MM Bayer / Cooper Technicon $ 500 MM SmithKline / International Clinical Laboratories $ 450 MM McKesson / Alco Health (Blocked by FTC injunction)$ 500 MM Chemical Venture Partners / TravCorps $ 50 MM LecTec / NDM (Subsidiary of Baxter)$ 35 MM Baxter (defense) Genentech (defense) Rorer Group (defense) Diasonics (defense)

Experience

1. Senior Managing Director

   Brock Capital Group

   Jun 2013 — Present · New York, NY, US

   Al Biloski works with high quality pharmaceutical and biotech companies, and their major investors, to optimize business and financial strategies. His multi-disciplinary 30+ year career in the healthcare field – with experience as a scientist, a big pharma employee, a venture capitalist and an investment banker - enables him to rapidly bring forward practical and actionable ideas to help clients achieve the best possible valuation. Dr. Biloski has led the seed round financings of a number of life science start-up companies in a diverse array of fields ranging from big data/AI to biotech and pharmaceutical services. As the lead pharma and biotech partner at Brock Capital, Dr. Biloski works with the independent fiduciary and family office groups to focus Brock Capital’s Opportunity Fund on the evaluation of direct investments in promising new companies.

Education

• Columbia University

  MBA, Banking, Corporate, Finance, and Securities Law

  1982 — 1984

• Yale University

  BS, Chemistry

  1974 — 1978

• Cornell University

  PhD, Chemistry

  1978 — 1982